ATUGEN
ATUGEN
Industry:
Biotechnology Health Care Medical
Founded:
1999-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Status:
Active
Similar Organizations
Activen
Activen is a biotechnology company specialised in drug discovery.
Advanced Genomic Technology
AGT is a biotechnology company based in Louisville, Kentucky.
Aneumed
Aneumed is a biotechnology company based in California, United States.
Boditech Med
Boditech Med is a biotechnology company based in Chuncheon.
Cellectis
Cellartis AB is a biotechnology company based in Sweden.
fasteris
Fasteris is a Swiss biotechnology company based in Geneva.
Myovec
Myovec is a company specialized in gene therapy.
Syndivia
Syndivia is a biotechnology company based in France.
More informations about "Atugen"
Atugen AG - VentureRadar
Atugen AG VentureRadar profile. Find out more about Atugen AG including the VentureRadar Innovation and Growth scores, Similar Companies and more. All; ... Ardena Belgium n/a Ardena is a fully integrated Contract Development & Manufacturing Organization (CDMO) with a core …See details»
Atugen - Crunchbase Company Profile & Funding
Organization. Atugen . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. A biotechnology company based in Berlin, Germany. Acquired by . …See details»
Atugen - Products, Competitors, Financials, Employees, …
Atugen. Frequently Asked Questions (FAQ) When was Atugen founded? Atugen was founded in 1998. Where is Atugen's headquarters? Atugen's headquarters is located at Robert Roessle …See details»
BioPharmaLink profile of Atugen AG, Germany,
Atugen has assembled a broad-based technology platform to bridge the gap between sequence information and gene function/target validation. These tools can be used to evaluate gene …See details»
Company Information - RocketReach
Atugen is a leader in RNAi therapeutics. This Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietary delivery system ("AtuPLEX") both …See details»
Atugen - Overview, News & Similar companies | ZoomInfo.com
Who is Atugen. Atugen is a leader in RNAi therapeutics. This Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a propri etary delivery …See details»
Atugen Biotech of Germany opens US research subsidiary
Jul 26, 1999 Atugen Biotechnology, the German integrated genomics company, hasestablished its North American research center as a subsidiary in Boulder, California. When the firm was …See details»
atugen AG raises EUR 5 million venture funding for siRNA …
Mar 16, 2004 Earlier this year atugen launched a new program to develop siRNA therapeutics. This program is designed to leverage attugen's accumulated know-how and proprietary …See details»
Atugen AG - Drug pipelines, Patents, Clinical trials - Synapse
Explore Atugen AG with its drug pipeline, therapeutic area, technology platform, 15 literature, Technology Platform:Small interfering RNA, Drug:Atu-014.See details»
Atu-014 - Drug Targets, Indications, Patents - Synapse - Patsnap
Atu-014: a RNA interference Drug, Initially developed by Atugen AG, Now, its global highest R&D status is Preclinical, Mechanism: RNA interference, Active Org.: Atugen AG. ... Active …See details»
atugen and Aventis to collaborate in identifying siRNA …
Berlin. atugen AG announced that it has signed a collaboration agreement with Aventis to identify siRNA compounds with the potential for therapeutic development. It is planned to combine …See details»
Silence Therapeutics - SR Pharma PLC - Acquisition(s)
Jun 21, 2005 SR PHARMA TO ACQUIRE ATUGEN Proposed acquisition and temporary suspension 21 June 2005 - London - SR Pharma plc ('SR Pharma' or 'the Company') is …See details»
Peter Buckel Appointed CEO of atugen AG - bionity.com
Jun 9, 2004 Peter Buckel brings to atugen his extensive experience in both the pharmaceutical industry and the biotechnology sector. His previous position was as co-founder and CEO of …See details»
Atugen Raises EUR5M As Fuel For SiRNA Drug Development
Mar 24, 2004 Atugen said the potency of siRNA in inhibiting target mRNA and, indirectly, protein expression, has been demonstrated to be 10- to 100-fold better than antisense …See details»
Research programme: siRNA therapeutics - Silence Therapeutics
Silence Therapeutics (formerly Atugen AG), is developing stabilised short (small) interfering RNA (siRNA) molecules, called AtuRNAi™, for the treatment of a ... If your organization has a …See details»
First US–German start-up - Nature Biotechnology
16, 812, 1998), Atugen is one of the first biotechnology firms with US parents to receive funding from the German government, which provided it with a cash handout of about $7 million. …See details»
OGS and atugen to work together on target validation
Dec 11, 2001 atugen AG of Germany has entered into a collaboration with the UK'sOxford GlycoSciences that will focus on the validation of disease-associated genetic targets of …See details»
Atugen Management Team - CB Insights
Explore {Atugen's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Atugen CEO, Founder, Key Executive …See details»
Atugen AG (Atugen AG) - 药物管线_专利_临床试验_投融营收_最新 …
了解Atugen AG (Atugen AG)公司的药物管线，治疗领域，技术平台，以及它的，技术平台:siRNA。See details»
Atu 027 - AdisInsight - Springer
Nov 4, 2017 Silence Therapeutics (formerly Atugen AG) was developing Atu 027, a small interfering RNA (siRNA) therapeutic, for the treatment of cancer. Atu 027 targeted the ... If …See details»